Funding for this research was provided by:
Centers for Disease Control and Prevention (CDC 000309CK14)
National Institutes of Health (NIH P01AI106705, NIH 5R01NS083687)
Charles S. Britton Fund.
Réseau National de Référence de maladies de Creutzfeldt-Jakob and the “Centre National de Référence des agents transmissibles non conventionnels
Investissements 276 d’avenir (ANR-10-IAIHU-06)
Italian Ministry of Health funding
Stivison Fund for CJD Research
Commonwealth Department of Health
NHMRC Practitioner Fellowship (APP1105784)
Grant-in-Aid for Scientific Research on Innovative Areas
Received: 5 December 2017
Accepted: 13 December 2017
First Online: 8 January 2018
Ethics approval and consent to participate
: All patient protocols were approved by the Institutional Review Boards of the University Hospitals Case Medical Center of Cleveland (# 05–14-09). The Australian National CJD Registry has ethical approval for its surveillance operations from The University of Melbourne Human Research Ethics Committee (#1341074.4). In all cases, according to the French regulation, the next of kin provided informed, signed consent in the name of the patient to permit an autopsy and neuropathological investigation. The national computerized registry of objection to autopsy was systematically consulted. <i>PRNP</i> had been analyzed pre-mortem with the signed consent of the France patient’s family. Data collection of clinically suspected cases is an integral part of the National CJD surveillance study, which was approved by the Ethic Committee of the Istituto Superiore di Sanità (CE-ISS 09/266 on 29 may 2009).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.